Celera Applera (Nasdaq: CRA) conducts business through two business segments: Applied Biosystems Group and Celera Genomics Group.
Celera Applera is a diagnostics business that delivers personalized disease management through a combination of products and services incorporating proprietary discoveries. They are organized into three reporting segments, a clinical laboratory testing service business (Lab Services), a products business (Products), and a segment that includes other activities under corporate management (Corporate).
The Lab Services business, conducted through Berkeley HeartLab, Inc. (BHL), offers a broad portfolio of clinical laboratory tests and disease management services designed to help healthcare providers improve cardiovascular disease treatment regimens for patients.
The Products business develops, manufactures, and oversees the commercialization of molecular diagnostic products. Most of this business is conducted through distribution and royalty agreements with Abbott Molecular, a subsidiary of Abbott Laboratories.
The Corporate segment includes revenues from royalties, licenses, funded collaborations and milestones related to the licensing of certain intellectual property and from our former small molecule and proteomic programs.
Source: Celera Applera May 11th, 2009 10-Q